{"organizations": [], "uuid": "94eadcae7faed3b71f7c11b61f46e40f545abf18", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180131.html", "section_title": "Archive News &amp; Video for Wednesday, 31 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sage-therapeutics-says-sage-217-me/brief-sage-therapeutics-says-sage-217-met-primary-endpoint-of-improved-sleep-efficiency-in-phase-1-2-study-idUSFWN1PQ0SW", "country": "US", "domain_rank": 408, "title": "BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.581, "site_type": "news", "published": "2018-01-31T19:14:00.000+02:00", "replies_count": 0, "uuid": "94eadcae7faed3b71f7c11b61f46e40f545abf18"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sage-therapeutics-says-sage-217-me/brief-sage-therapeutics-says-sage-217-met-primary-endpoint-of-improved-sleep-efficiency-in-phase-1-2-study-idUSFWN1PQ0SW", "ord_in_thread": 0, "title": "BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-sage therapeutics says sage-217 met primary endpoint of improved", "sentiment": "negative"}, {"name": "sage therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 31 (Reuters) - Sage Therapeutics Inc:\n* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS\n* SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT OF IMPROVED SLEEP EFFICIENCY AND DEMONSTRATED IMPROVEMENTS IN MAINTAINING SLEEP COMPARED TO PLACEBO\n* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL TOLERATED AND ALL ADVERSE EVENTS WERE MILD\n* SAGE THERAPEUTICS INC - BASED ON THE POSITIVE RESULTS, SAGE EXPECTS TO INITIATE CLINICAL DEVELOPMENT OF SAGE-217 IN DISORDERS OF SLEEP IN 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-31T19:14:00.000+02:00", "crawled": "2018-02-01T15:24:21.000+02:00", "highlightTitle": ""}